Drug Profile
Research programme: tumour infiltrating lymphocytes - Iovance Biotherapeutics/Ohio State University Comprehensive Cancer Center
Alternative Names: TIL - Iovance Biotherapeutics/Ohio State University Comprehensive Cancer CenterLatest Information Update: 28 Oct 2021
Price :
$50
*
At a glance
- Originator Iovance Biotherapeutics
- Developer Iovance Biotherapeutics; Ohio State University Comprehensive Cancer Center
- Class Antineoplastics; Immunotherapies; Tumour infiltrating lymphocyte therapies
- Mechanism of Action Immunologic cytotoxicity; Lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Haematological malignancies
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for preclinical development in Haematological-malignancies in USA (Parenteral)
- 06 May 2021 Iovance Biotherapeutics has multiple pending patent and granted patents for Gen 3 manufacturing, selected TIL products
- 07 Sep 2017 Iovance Biotherapeutics enters into a collaboration with Ohio State University Comprehensive Cancer Center for developing tumour infiltrating lymphocytes for Haematological malignancies